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ABSTRACT 
INTRODUCTION:  Bone marrow examination (BME) is performed in Human 
Immunodeficiency Virus-infected (HIV+) children with haematologic abnormalities 
to exclude specific disease (SD).  
AIMS: To describe the:  
(1) indications for BME , (2) utility of BME to diagnose SD, (3) patient 
characteristics associated with SD or non-specific disease (NSD). 
METHODS:  
Design: Retrospective review.  
Definitions:  
SD:  BME positive for opportunistic infection (OI) or HIV-related malignancy. 
NSD: HIV-related changes only. 
RESULTS: 
Eighty six BME’s were done. Suspected SD in 56/86(65.1%) was the most 
common clinical indication. Bicytopaenia(n=32) and isolated cytopaenia(n=31) 
were the most common haematologic indications. NSD 48/86 (55.8%) was a 
more common finding than SD 32/86 (37.2%). Granulomas, pure red cell aplasia 
and malignancy were the SD identified. Pre- highly active antiretroviral therapy 
(HAART), advanced stage, and not being virally suppressed were significantly 
associated with NSD. 
CONCLUSION: 
The yield of SD (37.2%) on BME is comparable to adult studies. HAART should 
be instituted before BME as NSD will be the most likely finding. 
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1.  INTRODUCTION & BACKGROUND 
 
 
1.1 Human Immunodeficiency Virus (HIV) – the face of the enemy 
 
HIV is responsible for essentially all cases of the acquired 
immunodeficiency syndrome (AIDS) in the Western world. Humans were 
first infected via zoonotic transmission of the virus from a chimpanzee (1), 
and transmission was enhanced by worldwide travel and urbanization.  
 
Based on mathematical modeling of HIV sequence variations, it is 
estimated that the first human infections with HIV occurred as early as the 
1930’s (2).  
 
The majority of HIV-infections in southern Africa today have sequence 
variation C, also referred to as clade C (3).   
 
HIV belongs to the family Retroviridae and the genus Lentiviridae. The 
virion measures 100 nanometer and contains two single RNA strands 
coated with the nucleocapsid protein. This viral RNA-protein complex core 
is enclosed in a capsid protein. The outer viral membrane (envelope) is 
acquired during budding from the host cell, while the glycoproteins (gp) 
embedded in this envelope, gp 41 and 120, are virally encoded. In 
addition to these structural proteins, the virion contains key enzymes 
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necessary for viral function, namely reverse transcriptase, integrase and 
protease (4).  
 
The complete life cycle of HIV is beyond the scope of this document, but is 
readily available for reference (4).  
 
The HI-virus infects CD4 T-lymphocytes having a cytolytic effect and 
depleting the CD4 T-lymphocyte pool over time. In addition to having 
direct cytotoxic effects on CD4 T-lymphocytes and cellular immunity, other 
mechanisms are also involved in causing the progressive destruction of 
the immune system (5). These mechanisms vary from inducing apoptosis 
through viral antigens to limitation of T-cell regeneration in the thymus and 
depleting the repertoire of antigen recognition. The T-cell proliferative 
response necessary for optimal B-cell function is adversely affected. 
Monocytes and macrophages are also infected by HIV, but instead of 
leading to cell death, these cells are used as reservoirs for latent infection. 
 
A patient with HIV-infection manifests a range of clinical features as the 
immune system is progressively destroyed. 
 
The clinical features of HIV-infection described in the untreated adult are 
those of an acute infection with flu-like symptoms (seroconversion) 
associated with a high-grade viraemia, followed by a variable 
asymptomatic period of immune containment of viral replication, and 
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finally progressive symptomatic immunocompromise with increasing viral 
loads, declining CD4 T-lymphocyte numbers and the occurrence of 
opportunistic infections (OI) and HIV-related malignancies.  
 
Depletion of the CD4 T-lymphocyte pool may not be as readily apparent in 
infants and young children as they have higher absolute lymphocyte 
numbers. In the paediatric population, dysregulated B-cell function with 
hypergammaglobulinaemia and the production of inappropriate polyclonal 
antibodies is more common than in adults. HIV-infected infants and young 
children without prior antigen exposure respond poorly to new 
environmental antigens and this leads to a greater frequency and severity 
of invasive bacterial infections at a young age (6). 
 
 
1.2 The scope of the HIV epidemic in South Africa and the paediatric 
context 
 
An estimated 64% of people living with HIV-infection are resident in sub-
Saharan Africa (7) and HIV-infection is a major public health problem in 
South Africa.  
 
The South African National HIV survey in 2008 (8) estimated that 10.9% of 
all South Africans over 2 years old were living with HIV-infection at the 
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time. This figure translates into 5.4 million people, 280 000 of whom are 
children under the age of 15 years. 
 
The prevalence in adults over the age of 25 years was 16.9%.  
 
The South African Department of Health study in 2008 (9) estimated that 
29.3% of pregnant women were living with HIV according to figures 
recorded based on data from antenatal clinic attendees.  
 
More than 95% of HIV-infected children less than 15 years of age contract 
HIV-infection through vertical transmission which may occur intra-uterine,              
peripartum, or through breastfeeding postpartum. Based on data from the 
Actuarial Society of South Africa (ASSA) 2003 study (7) (10), an estimated         
65 000 babies were infected during 2008, 39 000 babies were infected 
perinatally and 26 000 were infected through breastfeeding.  
 
Without optimal management, most children that acquire HIV-infection in 
utero or during the intrapartum period will have a more progressive 
disease course and 35% of these children will die by the age of one year, 
whilst 50% of these children will die by the age of 2 years. Adolescents 
and older children who acquire HIV by horizontal transmission follow an 
adult disease course with more slowly progressive disease.  
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HIV-infection is a major cause of the high under-five mortality rate (U5MR) 
in South Africa, and it has contributed to more than 40% of the under-five 
deaths in South Africa (11).  
 
The U5MR is a principal indicator used by the United Nations Children’s 
Fund (UNICEF) to assess human and economic progress in a country. 
The United Nations has set a millennium development goal to reduce the 
incidence of HIV-infection in children by 20% in 2005 and by 50% in 2010, 
and in so doing, decrease the U5MR (11).  
 
As noted by Saloojee (11), an important step towards reducing the 
incidence of HIV-infection in children is the prevention of mother to child 
transmission where the use of dual nevirapine and zidovudine (AZT) 
prophylaxis to mother and baby has reduced the absolute vertical 
transmission rate to approximately two percent. 
 
The HIV-epidemic has had far-reaching consequences for health care in 
South Africa in both the urban and rural health care settings. Up to 60% of 
all paediatric beds at hospitals are occupied by HIV-infected children at 
some point (11), and many more patients are seen as outpatients in 
community clinic-based primary healthcare.  
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An integral part of the management of patients with HIV-infection is the 
introduction of highly active antiretroviral therapy (HAART), but 
unfortunately, according to figures from June 2008 from the ASSA 2003 
model (10), an estimated 520 000 people in need of HAART (a combined 
figure for children and adults) would not have received it.  
 
The HAART-treatment guidelines for children have recently been reviewed 
by the Department of Health and recommend initiating HAART in all 
children less than 1 year of age irrespective of CD4 count, and 
significantly lowering the CD4 count at which children aged 1-5 years and 
children over the age of 5 years would qualify for HAART (12).  
 
Sadly, the picture of HIV-infection in children in the public health sector in 
South Africa is still bleak, with children presenting to public health care 
facilities with advanced HIV-infection, not on HAART, malnourished, with 
untreated OI’s, in poor social circumstances, either orphaned or with HIV-
infected, ill parents.  
 
As HIV-infection is a multisystem disease, a certain level of knowledge 
and skill is needed from health care workers in order to identify and 
manage the disease manifestations. The haematologic system is 
frequently affected, the features of which are described below.  
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1.3   The clinical effects of HIV-infection with emphasis on the 
haematologic system 
 
Haematologic abnormalities are among the most common manifestations 
of HIV-disease in the paediatric population and often produce multilineage 
blood defects (13). These abnormalities are initially detected on a 
peripheral full blood count and include various combinations of 
cytopaenias, including isolated cytopaenia (only one blood cell line 
abnormal), bicytopaenia (two blood cell lines abnormal) and 
pancytopaenia (three blood cell lines abnormal).  
 
These haematologic abnormalities are often the initial indication for 
requesting a bone marrow examination (BME) in order to elucidate the 
aetiology of these abnormalities.  
 
HIV-infection itself can be the cause of a central, bone marrow-related 
aetiology for the cytopaenias, as well as produce a peripheral mechanism 
of destruction to cause cytopaenias. 
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1.3.1  The effect of haematologic abnormalities on the staging of HIV 
infection  
 
The interim revised World Health Organisation (WHO) clinical staging of 
HIV/AIDS (14) for infants and children defines four stages of HIV-infection. 
Stage 1 refers to mainly asymptomatic children, and stage 4 refers to 
children with advanced immunosuppression and having AIDS-defining 
conditions.  
 
Haematologic abnormalities are defined in the WHO staging system as 
unexplained anaemia (<8g/dl), and/or neutropaenia (<500 cells/mm³), 
and/or thrombocytopaenia (<50 000 cells/mm³) for more than one month. 
If present, these haematologic abnormalities would place the patient in 
stage 3, defined as moderate immunosuppression.  
 
 
1.3.2   The effect of HIV-infection on central bone marrow haematopoiesis 
and cytokine expression 
 
Studies on the bone marrow cultures of HIV-positive patients have 
revealed that haematopoietic progenitor cell and colony growth were 
inhibited (15). The HI-virus was not isolated in these samples, suggesting 
that HIV has its effect on haematopoiesis through an indirect mechanism, 
rather than through direct infection of the progenitor cells. 
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Reduced colony growth was observed for colony-forming-unit 
multipotential haematopoietic progenitor cells (CFU-GEMM), colony-
forming-unit-granulocyte-macrophage progenitor cells (CFU-GM), 
megakaryocytic colonies (CFU-Meg) and erythroid progenitor colonies 
(burst-forming-unit-erythrocyte) (16). Controversy exists as to whether 
direct infection of CD34+ progenitor cells in the bone marrow occurs as 
they carry both the CD4 receptor and the CXCR4 co-receptor necessary 
for viral entry into the cell, but numerous investigators have found that 
these cells are not susceptible to direct infection by HIV in vitro or in vivo 
(17) (18).  
 
An alteration in the bone marrow micro-environment through infection of 
stromal cells, rather than direct infection of progenitor cells, is the most 
likely mechanism responsible for the abnormalities in haematopoiesis as 
described by Schwartz el al (19). Cytokine expression from stromal cells 
produces the signals to induce cellular differentiation in the progenitor 
cells and so regulate normal haematopoieisis.  
 
A dysregulation of cytokine expression from stromal cells produces 
abnormalities in progenitor cell differentiation leading to various 
dysfunctions in differentiation, and deviation from the lineage that the 
progenitor cell was originally committed to. The dysregulation of cytokine 
expression by bone marrow stromal cells and disordered haematopoieisis 
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is at its maximum in HIV-infected patients with advanced stages of 
immunosuppression with high viral loads and low CD4 counts (20). 
 
 
1.4   The effect of HIV-infection in producing a mechanism for peripheral 
destruction of blood cells  
 
HIV-infection affects the number and function of B-cells, and causes as an 
early abnormality a non-specific hypergammaglobulinaemia accounting for 
the high globulin fraction seen in the serum of HIV-positive patients. The 
presence of autoantibodies directed against blood elements may be 
explained by abnormal B-cell regulation by HIV-infected T-cells, direct 
activation of B-cells by HIV-infection or a B-cell response to coincident 
infection with Ebstein-Barr virus or cytomegalovirus (21) (22). These 
autoantibodies are directed against erythrocytes, platelets, and less 
commonly, leucocytes (23). Auto-antibody coated blood elements are 
destroyed in the reticulo-endothelial system and provide a mechanism for 
peripheral destruction of these cells. 
 
 
1.4.1   HIV-mediated autoantibodies directed against erythrocytes 
 
Autoimmune haemolytic anaemia (AIHA) results from the destruction of 
erythrocytes by autoantibodies. The anti-erythrocyte antibodies are 
 11 
caused by a general defect in the regulation of antibodies as occurs in the 
setting of HIV-infection. The presence of hypergammaglobulinaemia in 
patients with HIV-infection may result in the non-specific coating of the 
overabundant immunoglobulin G (IgG) to erythrocytes. Immune-complex-
associated IgG may also bind to erythrocytes via the C3b receptors on 
their cell surface and lead to their destruction through the activation of the 
complement pathway (24) (25).  
 
Various infectious agents that are frequently encountered in the setting of 
HIV-infection, namely Mycobacterium avium complex (MAC), 
Mycobacterium tuberculosis (MTB), Cytomegalovirus, Pneumocystis 
jiroveci, Parvovirus B19 and Histoplasma capsulatum may also be 
associated with the production of autoantibodies to erythrocytes (26). 
 
Although 20-40% of HIV-positive patients have a positive direct 
antiglobulin (Coombs) test, overt haemolysis due to these antibodies is a 
rare occurrence.  
 
Warm autoantibodies of the IgG type active at 37°C, and cold agglutinins 
of the immunoglobulin M (IgM) type active at 4°C have been described.  
 
Reticulocytopaenia is a frequent finding in the setting of HIV-associated 
haemolysis and may be explained by the abnormal bone marrow micro 
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environment that prevents the release of reticulocytes from the bone 
marrow (27).  
 
The current recommendation is that patients with a positive direct 
Coombs-result, minimal evidence of haemolysis, and a stable haematocrit 
level should be followed up clinically and not receive any specific 
treatment except HAART, as the autoantibodies present may be “clinically 
silent”.  
 
Treatment options available in the setting of clinically significant 
haemolysis include blood transfusions, corticosteroids, immunoglobulin 
therapy, other immunosuppressives and splenectomy (28). 
 
 
1.4.2   HIV-mediated autoantibodies directed against platelets 
 
Immune thrombocytopaenic purpura (ITP) occurs in HIV-infected children 
with elevated levels of platelet-associated IgG and/or circulating immune 
complexes. Patients with HIV-ITP often have platelet counts above 20 x 
109 cells/L and the overall incidence of haemorrage is low (29).  
 
Immune complexes contain anti-HIV gp120 and anti-idiotypes directed 
against the anti-HIV antibodies. Cross-reactivity has been described 
between antibodies against HIV gp120/160 and platelet gpIIb/IIIa. 
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Platelets coated with these antibodies and/or immune complexes are 
destroyed in the reticulo-endothelial system (30).  
 
The BME in patients with HIV-related ITP shows normal to increased 
numbers of megakaryocytes consistent with a peripheral destructive 
process (30).  
 
HIV-associated ITP has been described as a cause for thrombocytopaenia 
in HIV-infected patients with early stage HIV-infection and mild 
immunosuppression (23) 
 
The current recommendation for the management of patients with HIV-ITP 
is to institute HAART to reduce plasma HIV viraemia (31). Other treatment 
modalities should be reserved for patients with clinically significant, severe 
bleeding.  
 
These treatment modalities have varying degrees of success in 
ameliorating the thrombocytopaenia and include corticosteroids, 
immunoglobulins, other immunosuppresives, attenuated androgens and 
splenectomy (32).These agents are expensive and their durable response 
is poor. This emphasizes that the treatment of choice for patients with 
HIV-related ITP is HAART. This recommendation is based on the results 
of several studies that showed a significant increase in platelet count in 
patients on HAART (33) (34) (35).   
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1.4.3   HIV-mediated autoantibodies against leucocytes 
 
An autoimmune mechanism to account for granulocyte destruction has 
been postulated by some investigators, but has not been proven yet, 
especially in the paediatric setting (36). Secondary causes for leucopenia 
as discussed below should be given consideration first in HIV-positive 
patients with a low white cell count.  
 
 
1.5   The indications for a BME in HIV-positive children 
 
 The aetiology of bone marrow suppression is often multifactorial with 
haematinic deficiencies, OI’s, malignancies and drug side-effects 
contributing to the haematologic abnormalities in addition to HIV-infection. 
 
In an attempt to differentiate between some of these contributors, a BME 
is often requested. 
 
Indications for a BME quoted in adult literature include clinical indications 
such as pyrexia of unknown origin to exclude disseminated OI’s or 
neoplastic infiltration of the bone marrow (37).  
 
The most common indication for a BME though, is to explain 
haematological abnormalities, namely cytopaenias (38).  
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1.5.1  Cytopaenias as an indication for BME 
 
Cytopaenias may be the initial finding in children with undiagnosed HIV-
infection, and a high index of suspicion for HIV should be present when a 
child manifests with unexplained cytopaenias. Cytopaenias may involve 
one cell line (isolated cytopaenia), two cell lines (bicytopaenia) or three 
cell lines (pancytopaenia). Anaemia, thrombocytopaenia and leucopaenia 
may occur as an isolated finding or in various combinations.  
 
Morphologic abnormalities can be detected in the peripheral blood of HIV-
infected patients and include macrocytosis, reticulocytopaenia, circulating 
erythroblasts, granulocyte band-forms, immature myeloid cells, atypical 
lymphocytes and monocytes with cytoplasmic vacuoles and nuclear 
abnormalities (39).The presence of these haematologic abnormalities may 
prompt a BME to be done in an attempt to explain them, and to exclude a 
specific disease affecting the bone marrow.  
 
If cytopaenias alone was the indication for BME, it was associated with a 
finding of specific disease in only 4.9% (4/82) as shown by Tanaka et al 
from Brazil (40). In the same study it was shown that if the indication for 
the BME was anaemia as a single lineage cytopaenia, a specific disease 
was diagnosed in only 3.7% (3/82).  
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This Brazilian study (40) concurs with previous findings by Brooke et al 
(41), where a low yield was found if BME was done in patients with 
isolated thrombocytopaenia, anaemia or leucopaenia, as HIV was found to 
be the underlying cause.  
 
These studies highlight the fact that cytopaenias are common in patients 
with HIV-infection, but that a BME does not necessarily identify a specific 
disease besides HIV-infection as the aetiology of the cytopaenias. 
 
 A thorough knowledge of the possible aetiology of anaemia, 
thrombocytopaenia and leucopaenia as they pertain to HIV-infection is 
imperative in the care of paediatric HIV+ patients. These cytopaenias 
need to be investigated, explained, and where possible treated specifically 
in order to ameliorate their effects.  
 
 
1.5.1.1  Anaemia in HIV-positive children  
 
Anaemia is defined according to age-related values (42).  
 
Anaemia is the most common haematologic abnormality described in HIV-
infected patients and has been reported to occur in 60 – 80% percent of 
patients over the course of their disease.  
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The incidence of anaemia increases with the clinical stage of disease and 
is found in most HIV-positive patients with advanced stage disease (43).  
 
The significance of anaemia in children with HIV-infection is highlighted by 
Ellaurie et al (44), who found that anaemia was present in 94% of 100 
symptomatic, HIV-infected children, and that anaemia was a major 
predictor of disease progression. This emphasizes the importance of 
investigating anaemia in HIV-infected patients, and where possible, to 
correct the cause.  
 
The anaemia in HIV-infection is mostly of the normocytic, normochromic 
type as described by Perkocha et al (26), and the aetiology is often 
multifactorial.  
 
Two main pathophysiological processes produce anaemia either 
separately or in combination, namely through a central depression of 
erythropoiesis at the level of the bone marrow, and/or through the 
peripheral destruction of red blood cells by auto-immune mechanisms or 
sequestration of red cells.  
 
Anaemia of chronic disease secondary to central bone marrow depression 
of erythropoeisis is the most frequent cause of anaemia in HIV-positive 
patients. HIV-infection of bone marrow stromal cells disrupts cytokine 
expression as described above in section 2.1.  
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Cytokines such as tumour necrosis factor alpha and interleukin 1 have 
potent suppressive effects on bone marrow erythropoiesis (45).  
 
Erythropoietin (EPO), which is an important hormone regulating red cell 
production, failed to rise in response to the degree of anaemia in HIV-
infected patients, and a blunted EPO-response has been cited as a 
contributing factor in producing anaemia in these patients (46).  
  
Nutritional causes such as haematinic deficiencies of iron, folate and 
vitamin B12 suppress haematopoiesis and contribute to anaemia. A defect 
in iron utilization has also been suggested in patients with HIV-infection. 
Iron-staining of the bone marrow in these patients indicates normal 
storage iron in the presence of a decreased amount of iron in the 
normoblast red cell precursors (26). Vitamin B12 deficiency in HIV-
infected patients may be secondary to altered serum transport of vitamin 
B12 due to altered cobalamin transport proteins in patients with advanced 
HIV-disease (47). 
 
Certain drugs used in the treatment of HIV-infection and its complications 
may produce anaemia through bone marrow suppression. These drugs 
include AZT (48), trimethoprim-sulfamethoxazole, amphotericin B, 
gancyclovir and dapsone (49). A drug history is thus imperative in 
investigating the aetiology of anaemia in HIV-positive children.  
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Bone marrow infiltration by OI’s may disrupt erythropoiesis and cause 
anaemia. Disseminated MAC infection in HIV-positive patients is a 
common cause of anaemia in patients with advanced HIV-infection (50). In 
these patients, anaemia tends to occur out of proportion to the other 
cytopaenias.  
 
Other OI’s may disseminate to the bone marrow and suppress 
erythropoiesis in a similar way, namely MTB infection and disseminated 
fungal infections such as Histoplasma capsulatum.  
 
Human Parvovirus B19 can cause severe, recurrent anaemia in HIV-
infected patients. This single-stranded DNA-virus invade erythroid 
progenitor cells in the bone marrow via the group P antigen and replicates 
extensively in erythroid progenitor cells in the bone marrow. The erythroid 
progenitor cell is ultimately lysed. The inefficient humoral immunity present 
in HIV-positive patients allows the viraemia to persist and lysis of erythroid 
progenitor cells in the bone marrow continues until a pure red cell aplasia 
(PRCA) develop with a block in erythoid maturation and the characteristic 
presence of giant pronormoblasts is noted in the bone marrow (51). 
 
Bone marrow infiltration by a neoplastic process such as an HIV-
associated malignancy namely a non-Hodgkin’s lymphoma may depress 
erythropoiesis at the production level in the bone marrow resulting in 
anaemia. The myelosuppressive chemotherapy used in the treatment of 
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these malignancies also routinely causes anaemia.  AIDS-related 
lymphoma occurs late in the disease process in the setting of severe 
immunosuppression (52). 
 
 
1.5.1.2  Thrombocytopaenia in HIV-positive children 
 
Thrombocytopaenia is defined as a platelet count of less than 150 x 109 
cells/L across the age spectrum (42).  
  
Thrombocytopaenia has been reported to occur in 10-20% of HIV-infected 
patients (53).  
 
Isolated thrombocytopaenia may frequently be the presenting 
haematologic manifestation of HIV-infection (54). According to a study by 
Ellaurie et al (44), thrombocytopaenia is more likely to occur as an isolated 
haematologic abnormality than anaemia or leucopaenia and this may 
reflect the different mechanisms involved in producing cytopaenias.  
 
Anaemia and leucopaenia are more likely to be secondary to a central 
bone marrow depression and ineffective haematopoiesis and they occur 
later in the disease process. Thrombocytopaenia, especially in early stage 
disease, is caused by peripheral destructive mechanisms involving 
immune-based mechanisms. HIV-related ITP is the most common cause 
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of thrombocytopaenia through peripheral destruction in HIV-positive 
patients and HAART is recommended as the treatment of choice for this 
condition.  
 
Secondary causes of thrombocytopaenia in HIV-infected patients are 
drug-related bone marrow suppression, folate and vitamin B12 deficiency, 
infiltration of the bone marrow by OI’s or malignancy, hypersplenism and 
microangiopathic processes such as thrombotic thrombocytopaenic 
purpura (55).  
 
 
1.5.1.3  Leucopaenia in HIV-positive children 
 
Leucopaenia in children is defined according to age-related values and 
may include various combinations of lymphopaenia and/or neutropaenia 
(42). 
 
 The peripheral blood smear may show characteristic abnormalities 
associated with leucopaenia in HIV-positive patients. These abnormalities 
may include an increased number of circulating neutrophil band forms, 
immature myeloid cells, atypical lymphocytes and monocytes with 
cytoplasmic vacuoles and nuclear aberrations (39).  
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Lymphopaenia in HIV-positive patients refers to a decrease in the number 
of circulating lymphocytes. The HI-virus is a lymphotropic virus and cause 
lymphopaenia through infecting the CD4 T-lymphocyte and causing cell 
lysis through viral replication.  
 
HIV-uninfected CD4 T-lymphocytes may fuse with HIV-infected CD4 T-
lymphocytes and cause syncitiae with multinucleated giant cells that lyse 
easily. HIV-uninfected CD4 T-lymphocytes may further be lysed through a 
mechanism involving lymphocytotoxic antibodies that react with OKT4 
receptors on CD4-T-helper cells. Lymphopoiesis is often ineffective at a 
central bone marrow level in compensating for the above-mentioned 
mechanisms of loss of lymphocytes (56).  
 
Neutropaenia is a common finding among HIV-infected patients with 
advanced stage disease, and is present in 50-75% of these patients (57).  
As mentioned in the study by Ellaurie et al (44), leucopaenia, and 
specifically neutropaenia, is most commonly due to ineffective 
granulopoiesis secondary to HIV-related bone marrow suppression. HIV-
related anti-granulocyte antibodies have been described, but their 
correlation with neutropaenia is not 100%, and they are more common in 
adults (58).  
 
Hypersplenism from a variety of causes may lead to the peripheral 
destruction of leucocytes.  
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Drug side-effects provide an important aetiology of neutropaenia in HIV-
infected patients. These drugs are widely used and include dapsone, 
amphotericin B, antineoplastic chemotherapy, trimethoprim-
sulfamethoxazole, acyclovir, gancyclovir as well as AZT. Indeed, nearly 
50% of children taking AZT have been found to have absolute neutrophil 
counts of less than 750 cells/microlitre (59).  
 
Infiltration of the bone marrow by opportunistic pathogens such as 
mycobacterial and fungal organisms, and neoplasms such as a non-
Hodgkins lymphoma provide another mechanism for bone marrow 
suppression and resultant neutropaenia.  
 
Neutropaenia is more common in HIV-positive patients with an OI (65%) 
compared to those without an OI (34%) (44). Other confounding factors 
such as disease stage, and medication status should be taken into 
account when attempting to explain neutropaenia in these patients.  
 
Qualitative defects in neutrophil function have been described and these 
relate to abnormalities in chemotaxis, diapedesis, degranulation and 
intracellular killing via the respiratory burst system (60).  
 
Infants and children seem to tolerate low absolute neutrophil counts better 
with relatively infrequent infectious complications for the degree of 
neutropaenia. If, however, the neutropaenia is severe and prolonged, the 
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risk of serious bacterial infections and hospitalization increases 
proportionally (61).  
 
Several studies have suggested that quantitative and qualitative 
leucopaenia can be ameliorated by the use of HAART (62) (63). In the 
study by Huang et al (62), 66 HIV-infected patients were studied 
prospectively and a statistically significant increase was found in the total 
leucocyte and absolute neutrophil count after 6 months of initiating 
HAART.  
 
The HAART-regimens in this study included a protease inhibitor such as 
ritonavir or indinavir. Protease inhibitors have been shown to directly 
stimulate haematopoiesis and reduce apoptosis (63). As most of the 
HAART-regimens studied included protease inhibitors, these results are 
relevant mainly in the setting of protease inhibitor-containing HAART-
regimens.  
 
It is clear that cytopaenias are used as an important indication for a BME, 
and their aetiology can rarely be explained by one factor only. The overall 
value of cytopaenias to predict a specific disease affecting the bone 
marrow is low. The direct effect of HIV-infection plays a major part in 
producing cytopaenias, and a BME often merely confirms this fact.   
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This has led to the clinical question as to what the usefulness of a BME 
really is in HIV-positive patients in terms of diagnosing specific disease. 
 
If a BME is found to produce a high yield of specific disease, it may justify 
performing this invasive investigation on HIV-positive patients, and in 
particular, children.  
 
 
1.6   The bone marrow in HIV-positive children 
 
 
1.6.1  The morphology of the bone marrow in HIV-infection 
 
Several studies, mainly in HIV-infected adults, have been published that 
describe the characteristics of HIV-associated myelopathy (64) (65).  
 
Abnormalities have been reported in the cell lines and the matrix of the 
bone marrow. 
 
 
1.6.1.1 The cytological features of HIV-associated myelopathy 
 
The bone marrow in HIV-infected patients may be normocellular, 
hypocellular or hypercellular. Hypercellularity of the bone marrow has 
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been reported even in the presence of peripheral blood cytopaenias (66). 
Hypercellularity and peripheral blood cytopaenias often co-exist and 
reflect myeloid dysplasia and ineffective haematopoiesis.  
 
In a study by Mueller et al (67), bone marrow cellularity was evaluated 
specifically in a paediatric cohort, and hypercellularity was the most 
common finding. A diffuse lymphocytosis was the most common factor 
contributing to the hypercellularity.  
 
A lymphocytosis may be a normal finding in children, and cellularity is 
reported according to age-related norms. In this study (67), 
haematopoietic growth factors were also available to patients and 
contributed to the finding of hypercellularity. In this paediatric study (67), 
76% of patients were on antiretroviral therapy, but this was restricted to 
either monotherapy or two-drug combinations. These were not as effective 
as HAART, and there was still a high incidence of bone marrow 
abnormalities. 
 
Dysplasia has been noted in erythroid, myeloid and platelet precursors.  
 
Erythroid dysplasia is generally present in over 50% of patients, and 
erythrocyte precursors in the bone marrow may show nuclear aberrations 
including fragmentation and lobulation (68). Megaloblastic change that is 
unrelated to serum folate and vitamin B12 levels and/or treatment with 
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AZT has been reported. Similar findings of erythroid dysplasia have also 
been documented in a paediatric cohort (67). Myeloid dysplasia is 
characterized by left shifted, hyposegmented myeloid precursors and a 
maturation arrest at the metamyelocyte stage. High nuclear:cytoplasmic 
ratios, cleaved nuclei, and vacuolization in granuloblasts have been 
reported (69).  
 
Megaloblastosis and a left shift were the most common myeloid dyplastic 
features noted in paediatric patients (67).  
 
Megakaryocytic dysplasia is more common in patients with advanced 
stage disease. Changes affecting megakaryocytes relate mainly to nuclear 
abnormalities and include fragmented or denuded nuclei (70). Small, 
uninuclear megakaryocytes were found in paediatric HIV-patients, similar 
to those seen in myelodysplastic syndromes, but more rarely in adults 
(67).  
 
Abnormalities in plasma cell morphology are common in the bone marrow 
of HIV-infected patients, seen across the stage spectrum of the disease in 
31-85% of cases. The plasmacytosis may be related directly to HIV 
through a dysregulated B-cell proliferation, or be present secondary to 
antigenic stimulation due to another infection involving the bone marrow. 
Plasma cells were found to occur in clusters and showed nuclear 
abnormalities (70).  
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Bone marrow eosinophilia, without a concomitant peripheral blood 
eosinophilia is seen in 9-61% of patients (71). 
 
In adults, bone marrow iron stores were found to be adequate to 
increased and this indicates a defect in iron utilization, rather than an iron 
deficiency per se (72).  
 
In a paediatric cohort (67) however, 44% of patients had decreased or 
absent iron stores in the bone marrow, while only 26% had increased iron 
stores. This is in keeping with the common finding of iron deficiency in 
children. Serum iron studies can identify patients with an iron deficiency 
that may benefit from iron supplementation, and a BME is not needed to 
establish an iron-deficiency state.  
 
In a study by Harris et al in HIV-infected adults (71), well circumscribed 
and poorly defined lymphoid aggregates were described in up to 50% of 
patients with advanced stage HIV-infection. Some lymphoid aggregates 
may contain histiocytes and form noncaseating “loose” granulomas 
consisting of lymphocytes, plasma cells and histiocytes. In the majority of 
these patients, an infective cause for the granuloma formation was not 
found, and it was attributed to HIV-infection initiating histiocyte 
proliferation and promoting haemophagocytosis. The dysregulated 
cytokine profile in the bone marrow of HIV-infected patients plays a role in 
stimulating macrophage and histiocyte proliferation.  
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1.6.1.2 Abnormalities in the bone marrow matrix in HIV-associated 
myelopathy 
 
The bone marrow matrix may show fibrosis, increased reticulin fibers 
and “gelatinous” transformation (73). These abnormalities in the bone 
marrow matrix may be focal or diffuse. As a result of these 
abnormalities, bone marrow aspiration may be difficult, not infrequently 
yielding an insufficient specimen for analysis.  
 
 
1.6.2  The diagnostic utility of a BME in HIV-positive patients 
 
A BME is often performed in the clinical settings of unexplained pyrexia, 
unexplained haematological abnormalities, in the staging of previously 
diagnosed AIDS-related lymphomas and to exclude bone marrow 
involvement by disseminated OI’s and malignancies.  
 
The goal of a BME is to identify and differentiate between potentially 
treatable specific diseases in a timely manner. A potential advantage of a 
BME is that a specific diagnosis may be made rapidly in a critically ill 
patient based on histopathological examination of the core biopsy.  
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An important question that several earlier and more recent studies, as 
discussed below, aimed to answer is whether BME has a favourable risk 
to benefit profile to justify its use.  
 
In the pre-HAART period, an early retrospective study by Northfelt et al 
(74), found that 16% of patients had a mycobacterial infection diagnosed 
on BME, and the conclusion was made that a BME is a useful 
investigation for detecting mycobacterial infection in these patients.  
Similar findings were found by Engels et al (75) and Nichols et al (76), 
where mycobacterial or fungal infection was diagnosed by BME in 32% 
and 20% respectively.  
 
Benito et al (77) reported a yield of 37.9% of specific disease in HIV-
infected patients with unexplained pyrexia. These and other studies (78), 
(79) are from industrialized countries and the yield of specific disease on 
BME is reported between 22-42%. The diagnosis was unique in only 8-
10% of cases in industrialized countries with access to mycobacterial 
blood culture facilities.  
 
Several series have shown that a peripheral blood mycobacterial culture is 
as effective as a bone marrow mycobacterial culture in diagnosing 
mycobacterial infection (80) (81).  
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Akpek et al (82) found that the diagnostic sensitivity of peripheral blood 
mycobacterial cultures is greater than that of bone marrow histopathology 
alone, further reducing the potential unique value of a BME. 
 
In a retrospective study from South Africa by Karstaedt et al (83), the BME 
provided a yield of 38% of specific disease, and a unique diagnosis in 
24% of HIV-positive adults in the pre-HAART era. The patients in this 
study (83), all had advanced disease, as reflected by their in-hospital 
mortality of 23%, and none had received HAART. The specific diseases 
identified on BME were MTB in 32.3% (83/257), MAC in 1.6% (4/257), 
Cryptococcus in 1.6% (4/257) and haematological malignancy in 3.1% 
(8/257).  
 
This study (83) was done before lysis-centrifugation mycobacterial blood 
culture facilities were available in South Africa, and the authors concluded 
that the unique diagnostic yield of a BME would have been significantly 
less had these peripheral blood cultures been available as a first-line 
investigation in excluding disseminated mycobacterial infection.   
 
In a study from Brazil (40), mycobacterial infections were isolated in 
26.8% of cases. This study population were adults with advanced HIV 
infection and 85% of patients were prescribed HAART, but compliance 
was reported in only 65%.  
 
 32 
In both the South African (83) and Brazilian (40) studies, the incidence of 
mycobacterial infections was much higher than the 10% reported 
elsewhere (84), (85). This can be explained by the fact that South Africa 
and Brazil are countries with a higher prevalence of mycobacterial 
infection compared to other more developed countries. 
 
Mycobacterial infection may be associated with granuloma formation in 
different organs of the body. Granuloma formation was present in 44% 
(113/257) of patients in the study by Karstaedt et al from South Africa (83). 
In this study, the vast majority of patients with tuberculosis (92.8%) on 
bone marrow (BM) culture also had granulomata present on 
histopathological examination of the bone marrow. 
 
This high incidence of granulomata (44%) contrasts with the 20-30% 
incidence reported elsewhere (76), (79).  
 
A possible explanation for the higher incidence of granulomata in this 
study is that South Africa has a high overall incidence of mycobacterial 
infection, especially tuberculosis, compared with other more developed 
countries. 
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The presence of granulomata should alert the clinician to the high 
probability of an OI ranging from 80 to 100% in immunocompromised 
patients (41), especially in countries with a high incidence of 
mycobacterial infection.  
 
The caveat in this statement is that not all granulomata on BME are due to 
mycobacterial infection. 
 
The finding of a granuloma on a core biopsy is not pathognomonic for any 
one specific disease. Instead, its presence may be due to a variety of 
infectious and non-infectious causes.  
 
Non-infectious causes of BM granuloma include malignant diseases, 
notably the lymphoma group, where it is more common to find granuloma 
in association with Hodgkin’s disease than with non-Hodgkins lymphoma.  
 
Malignant causes have been described as the cause of BM granuloma 
formation in 20 – 25% of cases in adults (86). Other non-infectious causes 
include drugs such as procainamide and sulfonamide.  
 
Autoimmune diseases and sarcoidosis in adults were reported to cause 
BM granuloma less frequently (87).  
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In patients with advanced HIV infection, a 30% granuloma incidence was 
reported by Nichols et al (76).  The vast majority of these patients (80%) 
had an infectious cause for the granuloma, notably mycobacterial or 
fungal infection. In 20% of cases the cause of granuloma formation was 
undetermined, and it was suggested that these loosely cohesive, poorly 
organized granulomata can be due to the HIV-infection itself.  
 
Infectious causes of BM granuloma include viral, bacterial, mycobacterial, 
fungal and parasitic causes. Ebstein-Barr and cytomegalovirus are the 
most common viral causes, while Brucellosis and typhoid fever are 
bacterial causes of BM-granulomata in endemic areas. Disseminated 
fungal infection, in particular Histoplasmosis, is an important cause of BM-
granuloma, especially in patients with HIV-infection (87).  
 
Tuberculosis is one of the most common causes of BM-granuloma with 
reported incidence in the literature varying from 6 – 48%, and 33 – 100% 
in cases with disseminated tuberculosis  (87) (88). These series do not 
exclusively describe immunocompromised patients, and the lower 20 – 
30% incidence of granuloma formation (76) reported in HIV-positive 
individuals in some studies may be related to the inability of HIV-positive 
patients to mount a sufficient cellular immune response that is necessary 
for granuloma formation.  
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The pathological feature of caseation has historically been associated with 
tuberculosis, although in a study by Kinoshita et al (89), only 29% of 
patients had caseation necrosis. 
 
In addition to the finding of a low rate of caseation in cases with 
tuberculosis, it was found that the sensitivity of Ziehl-Neelsen (ZN) 
staining to identify acid fast bacilli (AFB) on microscopy of the bone 
marrow is low (76) (89). The proposed advantage of achieving a rapid 
diagnosis of specific disease by microscopy or histopathological 
identification of granulomata on BME may be outweighed by the low 
sensitivity of microscopy to identify AFB’s and the fact that the finding of 
granulomata in the bone marrow is non-specific. Nevertheless, as stated 
before (41), the presence of a BM granuloma in a country with a high 
tuberculosis incidence should prompt a careful search for tuberculosis by 
culture, and consideration should be given to institute empiric anti-
tuberculosis therapy pending the result of mycobacterial culture.  
 
Non-caseating BM granulomata have been described in small series of 
patients with MAC and disseminated Bacillus Calmette-Guerin (BCG) 
infection (90) (91). 
 
In the pre-HAART as well as the HAART era, mycobacterial infections 
were found to be the most common specific disease identified on BME of 
adults with advanced stage HIV-infection (92).   
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Controversy exists in the adult literature as to the value of a BME in 
diagnosing these infections.  
 
Akpek et al (82) concurred with previously documented findings (80) (81) 
that the diagnostic sensitivity of a blood and bone marrow mycobacterial 
culture is similar, but found that histopathological examination of bone 
marrow specimens resulted in the rapid identification of mycobacterial 
and/or fungal infections in a third of their patient cohort. Based on this, 
their recommendation is that the continued use of BME is justified.  
 
On the other hand, Marques et al (93) found that the maximum sensitivity 
on histology with combined mycobacterial stains was only 50%, and that 
granulomata were not sensitive for the detection of mycobacterial and/or 
fungal infections when culture-proven cases were evaluated together.  
The authors recommend a peripheral blood culture as the initial step in 
investigating disseminated mycobacterial or fungal infection.  
 
Few studies evaluate the value of a BME in diagnosing specific disease in 
the paediatric population exclusively.  
 
In one of the largest studies from the Paediatric branch of the National 
Cancer Institute, Mueller et al (67) described normal or HIV-related 
findings in the majority of patients with advanced HIV-infection.  
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Although 76% of these patients were on anti-retroviral therapy, most were 
on monotherapy or two-drug combinations, now known to be inferior to 
multi-drug HAART. Dyspoietic changes in the bone marrow were non-
specific and did not correlate with anti-retroviral therapy, age, stage of 
disease or the presence of OI’s. Bone marrow cultures were not more 
helpful than peripheral blood cultures in diagnosing OI. Repeated 
peripheral blood cultures were in fact more sensitive than morphology or 
culture of the bone marrow in diagnosing disseminated cytomegalovirus-
infection and MAC infection. The latter appears to be a unique finding in 
the paediatric population.  
 
Due to the paucity of data on the value of BME in the HIV-positive 
paediatric population, the aim of my study was to describe the indications 
used for a BME in a tertiary health care setting, the diagnostic utility of this 
investigation, and the clinical and haematologic features that may be 
associated with the finding of non-specific or specific disease on BME.  
 
Based on the literature review, the hypothesis is that non-specific HIV-
related changes will be the major finding in this cohort of patients with 
advanced disease stage and prior to the initiation of HAART. In South 
Africa, with its high prevalence of tuberculosis, the most common specific 
disease expected to be identified is opportunistic mycobacterial infection.  
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As described previously (67), cytopaenias alone and fever alone have low 
value in identifying specific disease on BME. If this finding can be 
replicated in this paediatric cohort, it may serve as a recommendation to 
reconsider the indications for a BME in paediatric clinical practice. 
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2.0 METHODS 
 
 
2.1 Study design 
 
A retrospective, cross-sectional descriptive study of HIV positive children 
that underwent a BME during the study period.  
 
 
2.2 Study site 
 
Chris Hani Baragwanath Hospital was the base hospital for patient 
selection and three study sites were included namely: 
 
1.) The General Paediatric wards at Chris Hani Baragwanath Hospital 
(Inpatients). 
 
The four general paediatric wards admit newly diagnosed children with 
HIV-infection and acute illnesses as well as children with known HIV-
infection requiring admission for an intercurrent illness. The incidence of 
HIV-infection among general paediatric admissions averages 30% 
(personal communication, Prof U Kala).  
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Haematologic abnormalities are commonly identified in this patient 
population when routine full blood counts are done. The identification of 
said haematologic abnormalities creates a common clinical dilemma - that 
is to decide what the relative importance of HIV-infection, and/or OI and/or 
HIV-related malignancy is in contributing to the abnormalities. This is an 
important question to answer as it has important treatment implications. 
The current practice is that the haematologists are consulted on these 
patients, and a BME is requested to assist in explaining the haematologic 
abnormalities.  
 
2.) The Harriet Shezi Paediatric HIV Outpatient Clinic at Chris Hani 
Baragwanath Hospital (Outpatients). 
 
Harriet Shezi Children’s Clinic is the public sector paediatric HIV clinic at 
Chris Hani Baragwanath Hospital. The clinic has started more than 2000 
children on HAART since the roll-out in April 2004. It is the largest single 
site paediatric HAART cohort known to date. The majority of children are 
referred here after hospital admission to continue management and follow-
up on an outpatient basis.  
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3.) The Paediatric HIV Research Unit (PHRU) at Chris Hani Baragwanath 
Hospital (Outpatients). 
 
PHRU was established as a prevention of mother-to-child transmission 
(PMTCT) site in 1996 and established as a paediatric clinic in 1998. It 
currently has 1280 children on HAART. 
 
The current practice is that outpatients from (2) and (3) with haematologic 
abnormalities are routinely discussed with the haematologists and in most 
instances referred to the haematology service for a BME. 
 
Permission was granted by the Chief Executive Officer (CEO) of Chris 
Hani Baragwanath hospital to review files for inpatients. Files for inpatients 
were obtained from the central records department at Chris Hani 
Baragwanath hospital. Files for outpatients were reviewed with permission 
from the heads of the Harriet Shezi and PHRU clinics respectively. The 
head of the Haematology Laboratory at the National Health Laboratory 
Service (NHLS) granted permission to access laboratory records. 
 
 
2.3 Study period 
 
The study was conducted by retrospective case-file review covering the 
three year period from 01 June 2006 to 01 June 2009.  
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2.4 Study sample  
 
Eighty six patients were identified that met the inclusion criteria (see 
below), and further data was available for 69 out of the 86 patients to 
describe the characteristics of those patients with either specific or non-
specific disease on BME.  
 
 
2.5 Study method and data collection 
 
A laboratory record listing all HIV-positive children that underwent a BME 
during the study period was obtained from the Haematology Laboratory at 
the NHLS. 
 
A BME was defined as a bone marrow aspiration and trephine core 
biopsy. The procedure is done under conscious sedation with 
cardiovascular monitoring and sterile precautions are followed.  
 
In the laboratory, bone marrow aspirates are stained with Giemsa stain. A 
standard method of reporting is followed to assess the overall cellularity of 
the specimen, the quality of haemopoiesis along the three cell lines, the 
relative proportion of lymphocytes, plasma cells and macrophages, the 
presence of viral inclusions and iron stores.  
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A ZN-stain is done to assess for the presence of AFB. No other routine 
mycobacterial stains are done. 
 
Trephine core biopsies are decalcified in 5% formic acid and tissue 
architecture is assessed. The cellularity of the specimen, the degree of 
fibrosis present and the presence of reticulin fibers, granulomas and 
abnormal infiltrates are described. Trephine biopsies are stained with PAS 
para-amino salicylic acid (PAS) and Grocotts methenamine silver stain to 
assess for fungi and non-tuberculous mycobacteria. 
 
Bone marrow aspirate material is incubated in a BACTEC 12B culture 
bottle containing 4ml of broth culture medium including antibiotics to 
suppress the growth of contaminants.  The BACTEC 460 (BD Diagnostics) 
instrument is used where the culture bottle is placed in an incubator at 35° 
Celsius, and if growth is present, carbon monoxide is released into the 
headspace of the instrument and the culture is designated as being 
positive. 
 
Once a bone marrow culture is found to be positive by the method 
described above, a ZN stain of the material is undertaken, and if positive, 
signifies the presence of mycobacterial growth. The identity of the 
organism (mycobacterial vs non-mycobacterial) can already be suspected 
on the morphology of the organisms on microscopy as tuberculous 
organisms show cording, but specifically designed probes are used to 
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distinguish between tuberculous (MTB-complex) and non-tuberculous 
mycobacteria (MAC).  
 
Blood or bone marrow material with a positive mycobacterial growth on 
the BACTEC culture media can be transferred into a mycobacterial growth 
indicator tube (MGIT) and a polymerase chain reaction (PCR) can then be 
done to distinguish the different species that form the MTB-complex 
namely MTB or Mycobacterium bovis. 
 
At present, a direct PCR is only validated for smear positive sputum on 
direct microscopy. All other specimens have to be incubated in the MGIT 
system first and subsequently undergo PCR-testing.  
 
Inclusion criteria for entry into the study were the following:  
(1) Age ≤ 16 years at the time of BME. 
(2) HIV positive diagnosis by HIV ELISA blood test after 18 months of age or 
by HIV PCR before 18 months of age.  
(3) Had a BME done during the study period.  
 
 The following patients were excluded from the study: 
(1) Patients who are HIV+ and underwent a first or follow-up BME as staging 
purposes for a non HIV-related malignancy, defined as all malignancies 
other than a non-Hodgkins lymphoma. 
 
 45 
Eighty six children met the inclusion criteria, and a retrospective case file 
review of these children was conducted.  
 
The files were reviewed to obtain the following information: 
 
2.5.1 Indication for BME  
1.) Clinical and/or 
2.) Haematological 
AND 
2.5.2 Major finding on BME 
1.) Specific disease or 
2.)  Non-specific disease or 
3.) Insufficient sample 
 
 
2.5.1 Indication for BME: 
 
Indications for a BME were divided into clinical and/or haematologic 
indications.  
 
1.) Clinical 
Clinical indications were defined as the suspicion of an OI or HIV-
related malignancy, based on the presence of unexplained, new or 
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enlarging lymphadenopathy, and/or hepatosplenomegaly, and/or 
loss of weight, and/or persistent pyrexia.  
 
Staging was chosen as a clinical indication if the BME was done as 
part of a staging work-up for an already diagnosed HIV-related 
malignancy (non-Hodgkins lymphoma) elsewhere (e.g. a fine 
needle aspirate or biopsy of a lymph node or mass lesion indicating 
an HIV-related malignancy.)  
 
2.) Haematological 
Haematologic indications were defined as the presence of an 
isolated cytopaenia (one cell line abnormal), bicytopaenia (two cell 
lines abnormal), or pancytopaenia (all three cell lines abnormal).  
Anaemia and leucopaenia were defined according to age-related 
values, and thrombocytopaenia as a platelet count of less than    
150 x 109/L (42).   
 
 
2.5.2 Major finding on BME 
 
The findings on the BME were grouped into findings on 
microscopy/histopathology and finding on bone marrow culture result in 
order to determine whether specific disease, non-specific disease, or an 
insufficient sample were present. 
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1.) Specific disease (SD) 
Defined as: 
  
Microscopic identification of AFB’s, granulomata, fungal 
elements, malignant infiltrate or pathological features 
suggestive of a PRCA. 
 
Any collection of epithelioid histiocytes was regarded as a 
granuloma. As mentioned in section 1.6.2, granulomata are a 
common manifestation of disseminated tuberculosis, especially in 
countries with a high tuberculosis prevalence such as South Africa. 
Therefore, the presence of granulomata in the bone marrow of our 
patient cohort was taken as indicative of disseminated tuberculosis.  
 
The presence of fungal hyphae was defined as fungal elements. 
 
 A PRCA was present if giant pronormoblasts, severely depressed 
selective erythrocyte maturation and/or the direct visualization of 
viral inclusions in erythrocyte precursors were present.  
 
A disseminated HIV-related malignancy was defined as bone 
marrow involvement by a non-Hodgkin’s lymphoma 
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OR 
 
Bone marrow cultures positive for mycobacterial organisms  
  and/or positive viral studies. 
 
A positive bone marrow culture of MTB-infection or non-tuberculous 
mycobacterial infection namely MAC infection, and Mycobacterium 
bovis infection. PCR to detect mycobacterial DNA in specimens 
was not widely available at the time of this study. 
 
A positive PCR for Parvovirus B19, if done, confirmed the presence 
of Parvovirus infection. Fungal cultures of bone marrow are not 
routinely done at this institution. 
 
 2.) Non-specific disease (NSD) 
 Defined as:  
 
Non-specific HIV-related changes, anaemia of chronic disorder 
and “peripheral cause for cytopaenia” without the concomitant 
presence of SD 
 
The features of HIV-related myelopathy were described in section 
1.6.1.1. In accordance with this, non-specific HIV-related changes 
were present if the BME yielded any of the following: 
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hypercellularity, myelodysplasia, disordered hematopoiesis, 
plasmacytosis and lymphocytic and histiocytic infiltrates without 
granulomas. Anaemia of chronic disorder was present if there were 
features of increased iron deposition in bone marrow macrophages, 
together with sideropaenia. A “peripheral cause for cytopaenia” was 
present if the BME was normal in the presence of cytopaenias, and 
would suggest the possibilities of immune destruction or 
hypersplenism.  
 
If both specific disease as well as non-specific findings were 
present, the BME was classified under “SD”. 
 
 3.) Insufficient sample (IS) 
 Defined as: 
 
 An inability to comment on the bone marrow sample due to the 
sample being too haemodilute, or not containing enough marrow 
spaces to comment meaningfully on possible pathology, or samples 
not containing bone marrow at all. 
 
(See complete Data Collection sheet 1 in Appendix A) 
 
 
 50 
Further data was available for 69 out of the 86 patients to describe the 
characteristics of those patients with either SD or NSD identified on BME.  
 
The following variables were recorded in order to describe the 
characteristics of HIV+ patients that had a BME done: 
 
1.) Age and sex of the patient. 
2.) Clinical stage of HIV infection as defined by the WHO (14) 
 Stages 1-4 
3.) Immunological category as reflected by the CD4 count (14) 
 Category 1: CD4 ≥ 25% 
 Category 2: CD4 15-24% 
 Category 3: CD4 < 15% 
4.) Virological stage as reflected by whether the patient is virally suppressed 
or not. 
 Viral suppression: < 25 viral copies/ml of blood 
5.) Haematologic profile of the patient – Whether an isolated cytopaenia, 
bicytopaenia or pancytopaenia is present. 
6.) Treatment status namely whether the patient is taking HAART or not. On 
HAART was defined as patients taking HAART for ≥ 3 months duration 
and without an interruption in treatment in the 3 months preceding the 
BME (14). 
7.)  Potentially marrow suppressive drugs the patient was taking (excluding 
HAART). These drugs were defined as taking cotrimoxazole (Bactrim), 
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gancyclovir, dapsone, amphotericin B, and/or anti-neoplastic 
chemotherapy.  
8.) The concomitant presence of a documented serious bacterial infection 
that may contribute to bone marrow suppression. 
9.) The presence of a documented haematinic deficiency namely iron, vitamin 
B12 or folate deficiency. These deficiencies may contribute to 
haematological abnormalities.  
10.) The presence of a known HIV-related malignancy or opportunistic 
infection at the time of analysis. An already diagnosed HIV-related 
malignancy or opportunistic infection elsewhere may disseminate and 
involve the bone marrow with resultant haematologic abnormalities.  
 
(See complete data Collection sheet 2 in Appendix B) 
 
 
2.6 Data analysis 
 
Data was collected on 2 separate Microsoft Excel data collection sheets 
attached in Appendices A and B.  
 
The data was analysed using the Stata Statistical software package 
version 10.1 in conjunction with a biostatistician. 
 
 52 
Associations between patient characteristics and bone marrow findings 
were tested using the Fisher’s exact and chi-square tests for categorical 
variable analysis. 
 
 Statistical significance was set at p ≤ 0.05. 
 
 
2.7  Ethics 
 
Individual patient data was coded with a unique number and access to 
patient files was restricted to the investigator and study supervisor. It was 
in no way necessary to reveal a patient’s identity in the final paper and 
adherence to strict levels of confidentiality was adhered to at all times. 
 
Ethics approval was obtained from the Ethics Committee of the University 
of the Witwatersrand. (Reference number: M090913) 
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3.0 RESULTS 
 
Eighty six patients had a BME done during the study period from the three 
study sites. 
 
 
3.1 The clinical indications for performing a BME and the yield per 
clinical indication on BME 
 
The most common clinical indication for performing a BME was the clinical 
suspicion of a disseminated OI or malignancy in 65.1% of (56/86) cases.  
 
Other indications for a BME were bone pain (n=1) and ascites (n=1). In 
15.1% (13/86) there were no clinical indications for the BME. 
 
Figure 3.1 The clinical indications for performing a BME (n=86) 
 
Suspected opportunistic infection or malignancy - 65.1% (56)
Staging for known malignancy - 17.5% (15)
Other - 2.3% (2)  (Bone pain 1; Ascites 1)
No clinical indication - 15.1% (13)
 
 54 
The association between different clinical indications and the findings on 
BME was tested with chi square and Fisher’s exact tests and, as can be 
seen from table 3.1 below, no statistically significant associations were 
found between specific clinical indications and findings on BME. 
 
Table 3.1 The relationship between clinical indications and findings on 
bone marrow examination 
 
 
 
 
 
 
 
 
Pearson chi2 p = 0.662    
Fishers exact p = 0.748 
 
 
 
 
 
 
 
BMAT 
findings 
(n=86) 
Suspected 
OI/malignancy 
% (n=56) 
Staging for 
known 
malignancy 
% (n=15) 
Other 
% (n=2) 
No clinical 
indication 
% (n=13) 
Specific 
disease 
41.1% (23) 33.3% (5) 0 (0) 30.8% (4) 
Non-
specific 
disease 
50.0% (28) 66.7% (10) 100% (2) 61.5% (8) 
Insufficient 
sample 
8.9% (5) 0 (0) 0 (0) 7.7% (1) 
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3.2 The haematologic indications for performing a BME and the yield per 
haematologic indication on BME 
 
Isolated cytopaenia in 37.2% (32/86) and bicytopaenia in 36.0% (31/86) of 
patients were the most common haematologic indications for a BME.  
 
Pancytopaenia was present in 19.8% (17/86) of patients.  
 
No haematologic indication for the BME was present in 7.0% (6/86) of 
patients. 
 
Figure 3.2 The haematologic indications for performing a BME (n=86) 
Isolated cytopaenia - 37.2% (32)
Bicytopaenia - 36.0% (31)
Pancytopaenia - 19.8% (17)
No haematologic indications - 7.0% (6)
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Patients who had an isolated cytopaenia as haematologic indication for 
the BME had isolated anaemia in 78.1% (25/32) of cases, and an isolated 
thrombocytopaenia in 21.2% (7/32) of cases. No patients had an isolated 
leucopaenia as haematologic indication for BME.  
 
Of those patients with an isolated anaemia as indication for BME, 52% 
(13/25) had specific disease on BME, and 48% (12/25) had non-specific 
disease as finding on BME. 
 
Table 3.2.1 The specific disease identified on BME where isolated 
anaemia was the haematologic indication for performing the BME 
 
 
 
 
 
 
 
No patient who had an isolated thrombocytopaenia (7/32) as haematologic 
indication for BME had specific disease as finding on BME.  
 
The association between different haematologic indications and the 
findings on BME was tested with chi square and Fisher’s exact tests and 
no statistically significant associations were found between specific 
haematologic indications and findings on BME. 
 
Specific disease identified (n=13) 
Parvovirus infection 7 
Non-Hodgkins lymphoma 3 
MAC 2 
MTB Complex 1 
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Table 3.2.2 The relationship between haematologic indications and 
findings on bone marrow examination 
 
 
 
 
 
 
 
 
Pearson chi2 p = 0.336 
Fishers exact p = 0.336 
 
 
3.3 Patients with both clinical and haematologic indications for 
performing a BME 
 
The majority of patients had both clinical and haematologic indications for 
a BME in 77.9% (67/86). 
  
 
 
 
BMAT 
findings 
(n=86) 
Isolated 
cytopaenia 
% (n=32) 
Bicytopaenia 
% (n=31) 
Pancytopaenia 
% (n=17) 
No 
hematologic 
indication 
% (n=6) 
Specific 
disease 
40.6% (13) 38.7%(12) 41.2% (7) 0 (0) 
Non-
specific 
disease 
56.3% (18) 51.6% (16) 47.1% (8) 100% (6) 
Insufficient 
sample 
3.1% (1) 9.7% (3) 11.8% (2) 0 (0) 
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Table 3.3 Patients with both clinical and haematologic indications for 
performing a bone marrow examination 
 
  
 
 
 
 
3.4 The findings on BME and the utility of BME to diagnose specific 
disease 
The table below lists the findings on BME: 
 
Table 3.4.1 Individual findings on BME 
Findings on BMAT (n)* 
Non-specific changes only 48 
Granulomas 12 
PRCA 11 
Malignancy 7 
Bone marrow culture positive 7 
Insufficient sample 6 
* Total adds up to >86 as some had more than one finding on BME 
  
Non specific HIV-related changes indicative of HIV myelopathy namely 
hypercellularity, myelodysplasia, disordered hematopoiesis, plasmocytosis 
and lymphocytic and histiocytic infiltrates without granulomas, anaemia of 
chronic disorder and  “peripheral cause for cytopaenia”, were the major 
finding on BME in this cohort of patients  in 55.8% (48/86).  
 
Indications % (n=86) 
Clinical OR 
hematologic 
22.1% (19) 
Clinical AND 
hematologic 
77.9% (67) 
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SD, namely the presence of granulomas, PRCA, malignant changes, and 
positive bone marrow cultures comprised 37.2% (32/86) of the total.  
 
No patients had fungal elements identified on microscopic examination of 
the BME. Only 16.7% (2/12) of patients with granulomas on BME had a 
positive ZN-stain.  
 
In 7.0% (6/86) of cases, the samples were insufficient for analysis.  
 
    Table 3.4.2 Specific vs Non-specific disease on BME 
  
 
 
 
  
 
3.4.1 SD on BME 
 
SD identified on BME were granulomas (n=12), PRCA (n=11), malignancy 
(n=7), and positive BM culture (n=7). 
 
 
 
 
Findings on BMAT % (n=86) 
NSD only 55.8% (48) 
SD 37.2% (32) 
IS 7.0% (6) 
 60 
3.4.1.1 Granulomas (n=12) 
 
 All patients with granulomas on BME had a ZN-stain done, and of these, 
only 16.7% (2/12) were positive. Most patients with granulomas identified 
on bone marrow microscopy had a negative bone marrow culture for an 
opportunistic pathogen in 58.3% (7/12). The remaining five patients 
(41.2%) with granulomas on bone marrow also had a positive bone 
marrow culture namely MAC (n=3), and MTB Complex (n=2).  
 
Two patients with positive bone marrow cultures had no granulomas on 
pathological examination of the bone marrow, one each with MAC and 
MTB Complex. 
 
Further data was available for 10/12 patients who had granulomas on 
BME.  
 
Patients with the finding of bone marrow granulomata were severely 
immunosuppressed as evidenced by having stage four clinical disease in 
all (n=10), the majority in immunological category three (n=7), and not 
virally suppressed (n=8).  
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Most patients with granulomata on bone marrow, were not on anti-
retroviral therapy (n=7), with only 3/10 on HAART. The 3 patients on 
HAART with granulomata on BME had the following characteristics based 
on available data: 
 
1.) One patient was on HAART for an unknown duration, but had an 
unsuppressed viral load. The patient was on treatment for MTB, but 
MAC was cultured on the bone marrow mycobacterial culture. 
2.) One patient was on HAART for 4 years and was virally suppressed. 
Granulomatous inflammation as well as HIV-related changes was 
identified on the BME, but both the ZN-stain and bone marrow 
mycobacterial culture were negative. 
3.) One patient was on HAART for 6 months. Data was not available 
with regard to viral load after the start of HAART. The patient was 
on treatment for disseminated MTB already, but had received a 
shortened intensive phase of treatment. 
 
Patients with granulomata on bone marrow had pancytopaenia (n=5) as 
the most common haematologic abnormality, with bicytopaenia in 4/10 
and isolated cytopaenia in 1/10 of patients. 
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3.4.1.2  PRCA (n=11) 
 
Seven patients had giant pronormoblasts on morphological examination of 
the BME, which is pathognomonic of Parvovirus infection of the bone 
marrow. Four patients had microbiologically proven Parvovirus infection of 
the bone marrow with PCR positive for Parvovirus on the bone marrow.  
 
 
3.4.1.3  Malignancy (n=7) 
 
All patients with an HIV-related malignancy involving the bone marrow 
(n=7), had infiltration of the bone marrow by a non-Hodgkins lymphoma. In 
most cases, the diagnosis of malignancy was already made from another 
site, and BME was done for staging purposes (n=5). In two patients, the 
malignancy was primarily diagnosed on BME.  
 
A total of 15/86 patients underwent a BME as a staging procedure, and of 
these, 33.3% (5/15) had bone marrow involvement by the malignancy. 
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3.4.1.4  Positive bone marrow cultures (n=7) 
 
Positive bone marrow cultures were present in 8.1% (7/86) of patients. 
The responsible organisms were mycobacteria in all seven cases – three 
with MTB-complex and four with MAC. 
  
Table 3.4.3 Bone marrow culture findings 
 Bone marrow culture % (n=86) 
Positive 8.1 % (7) 
Negative 91.9% (79) 
 
Table 3.4.4 Organisms grown from bone marrow culture 
 Organism (n=7) 
MTB Complex 3 
MAC 4 
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3.5 Characteristics of patients that underwent a BME 
 
Data was available for 69 out of the 86 patients who underwent a BME to 
determine the characteristics of patients undergoing a BME.  
 
 
3.5.1  Gender and age 
 
A BME was done in 55.1% (38/69) of males and 44.9% (31/69) of 
females. The majority of patients were >5 years of age in 56.5% (39/69), 
1-5 year age group were 37.7% (26/69), and the minority were less than 1 
year of age 5.8% (4/69). 
 
 
3.5.2   Clinical, immunological and viral disease status 
 
The clinical stage of patients who underwent a BME were stage four 
71.0% (49/69) in the majority of cases, with stage three 18.8% (13/69), 
stage two 8.7% (6/69) and stage one 1.4% (1/69) comprising the 
remainder.  
 
Most patients had immunologically advanced disease in immunological 
category three 71.0% (49/69), with 18.8% (13/69) in immunological 
category two, and 10.1% (7/69) in immunological category one.  
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Most patients were not virally suppressed at the time of BME with 88.4% 
(61/69) having a viral load of >25 copies/ml, and only 11.6% (8/69) being 
virally suppressed with a viral load of <25 copies/ml. 
 
 
3.5.3 Antiretroviral and other medication status 
 
The majority of patients were not on HAART in 73.9% (51/69), with 26.1% 
(18/69) patients on HAART. Only 31.9% (22/69) of patients were taking 
other medication defined as any of the following: cotrimoxazole (Bactrim), 
gancyclovir, dapsone, amphotericin B, and anti-neoplastic chemotherapy. 
Most patients were not taking any other medication    68.1% (47/69). 
 
 
3.5.4 Haematologic abnormalities and presence of haematinic deficiency 
 
Bicytopaenia in 37.7% (26/69) and isolated cytopaenia in 34.8% (24/69) 
were more common than pancytopaenia in 21.7% (15/69) in this cohort, 
while 5.8% (4/69) had no haematologic abnormalities. An isolated 
anaemia was the most common isolated cytopaenia identified. 
 
Data was available in 85/86 patients with regard to the mean cellular 
volume (MCV) of the erythrocytes. The MCV-value is used to guide 
investigations into an underlying haematinic deficiency as a cause of 
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anaemia. MCV-values are age-specific (42), and are routinely available 
when a standard full blood count test is done.  
 
In this cohort of patients, 64.7% (55/85) had normal MCV-values. Despite 
normal MCV-values, 29% (16/55) of patients had haematinic 
investigations done. These investigations included 15 iron studies, 10 
vitamin B12-levels and 6 folate levels. The majority of patients with normal 
MCV-values that had haematinic investigations done, had no deficiency 
identified in 62.5% (10/16), while an iron-deficiency state was identified in 
83.3% (5/6). 
 
A high MCV was present in 23.5% (20/85) of patients. The majority of 
these patients had no haematinic investigations done in 65% (13/20). Of 
those that had haematinic investigations done, 5 iron studies, 5 vitamin 
B12-levels and 3 folate levels were done. No deficiency was identified in 
any of the patients with a high MCV. The majority of patients with a high 
MCV were taking HAART already in 70% (14/20), and one patient was on 
anti-epileptic medication. 
 
A low MCV was present in 11.8% (10/85) of patients. Of these, 70% (7/10) 
had haematinic investigations done. These investigations included 7 iron 
studies, 3 vitamin B12-levels, and 4 folate levels. A deficiency was 
identified in all 7 patients that had haematinic investigations done, and all 
7 had an iron-deficiency state.  
 67 
3.5.5 Presence of concomitant septicaemia at the time of BME 
 
Only one patient, 1.4%, had a positive bacterial blood culture at the time of 
BME, the organism was Salmonella paratyphi. This patient was not on 
antiretroviral therapy and had advanced immunosuppression (clinical 
stage four and immunological category three) with pancytopaenia. Four 
patients (5.8%) had no bacterial blood culture sent at the time of 
undergoing the BME, and 92.3% (64/69) had negative bacterial blood 
cultures at the time of BME. 
 
 
3.5.6 Known presence of an OI or HIV-related malignancy at the time of 
BME 
 
Most patients, 71.0% (49/69), had no known OI at the time of BME. Fewer 
patients, 29% (20/69), were already on treatment for an OI at the time of 
BME: 18 patients on treatment for MTB, 1 patient on MAC treatment and 1 
patient with previously positive Parvovirus IgM and IgG serology. A 
previously diagnosed non-Hodgkins lymphoma was present in 14.5% 
(10/69) of patients, who underwent the BME as part of the staging workup.  
 
The characteristics of patients who ultimately had SD and NSD as finding 
on BME are described in table 3.5. 
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Associations were tested between different patient characteristics and 
findings on BME. 
 
As shown below, statistically significant associations were observed 
between clinical disease stage (p=0.05), viral load status (p=0.03), anti-
retroviral treatment status (p=0.05) and the finding of NSD (HIV-related 
changes) on BME. Further to this, advanced clinical disease stage, not 
being virally suppressed, and not taking HAART were statistically 
significantly associated with the finding of NSD on BME as calculated by 
the chi square and Fisher’s exact tests. 
 
No statistically significant associations were observed between the other 
characteristics as listed in the table below and finding on BME.  
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Table 3.5 Clinical characteristics of patients who underwent BME and 
their association with the findings on BME 
Clinical features BM Specific 
disease (n=25) 
BM Non 
specific 
disease 
(n=42) 
BM insufficient 
(n=2) 
Significance 
p ≤ 0.05 
Sex    NS 
     Male 16 21 1  
     Female 9 21 1  
Age    NS 
    < 1 year 1 3 0  
     1-5 years 7 17 2  
     > 5 years 17 22 0  
Clinical stage    S (p=0.05) 
     Stage 1 0 1 0  
     Stage 2 0 6 0  
     Stage 3 2 11 0  
     Stage 4 23 24 2  
Immunological 
category 
   NS 
     Imm Cat 1 0 6 1  
     Imm Cat 2 5 8 0  
     Imm Cat 3 20 28 1  
Viral Load    S (p=0.03) 
     VL <25  5 2 1  
     VL ≥25 20 40 1  
HAART    S (p=0.05) 
     Pre-Haart 15 35 1  
     On Haart 10 7 1  
Other treatment    NS 
     Yes 10 11 1  
     No 15 31 1  
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Haematologic 
abnormalities 
NS 
Isolated cytopaenia 10 13 1  
Bicytopaenia 8 18 0  
Pancytopaenia 7 7 1  
No abnormality 0 4 0  
Haematinic deficiency                                        NS 
Fe/VitB12/Folate 
deficiency 
5 7 0  
Test not done 8 26 2  
No deficiency 12 9 0  
Bacterial Blood 
culture  
   NS 
     Positive 1 0 0  
     Negative 24 38 2  
Not done 0 4 0  
Known OI    NS 
     Yes 7 12 1  
     No 18 30 1  
Known HIV 
malignancy 
   NS 
     Yes 3 7 0  
      No 22 35 2  
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4.0 DISCUSSION 
 
Health care practitioners that consult haematologists to request a BME on 
an HIV positive child are not uncommon in current day paediatric clinical 
practice.  
 
A common clinical dilemma is that of an HIV positive child with 
haematologic abnormalities such as cytopaenias, identified on a 
peripheral blood count done as an in- or outpatient. This raises the 
important question of whether HIV infection is the major contributor to the 
abnormalities in blood parameters, or if, in addition, a SD, is involving the 
bone marrow with resultant cytopaenias. 
 
This question is very relevant as it has major treatment implications. 
 
In this study, I set out to determine what indications are used by health 
care workers in a tertiary hospital in both in- and outpatient settings when 
requesting a BME on an HIV positive child, as well as what the yield per 
indication for BME is.  
 
I further aimed to determine what the utility of this invasive investigation is 
in order to diagnose SD.  
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Combining clinical, laboratory and therapeutic data, I aimed to describe 
patient characteristics that are associated with either NSD (HIV-related 
changes only on BME) or SD (disseminated OI or malignancy on BME). 
 
 
4.1   The indications for performing a BME 
 
A paucity of data exists on the indications for and utility of a BME in the 
paediatric population, with most studies reported in adults (94). Common 
indications (both clinical and haematological) for a BME used in adult 
studies are pyrexia of unknown origin, cytopaenias, a search for 
opportunistic pathogens and to exclude infiltration of the bone marrow by 
a neoplastic process (37) (75). 
  
 In the current paediatric study, the majority of patients had both clinical 
and haematologic indications for performing a BME in 77.9% (67/86). The 
indications for performing a BME were similar to those from above-
mentioned adult studies, namely a suspicion of disseminated OI or 
malignancy accounting for the major clinical indications to perform a BME 
in 65.1% (56/86).  
 
In this study, isolated cytopaenia in 37.2% (32/86), and bicytopaenia in 
36.1% (31/86) of patients were the most common haematologic 
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indications for a BME. Pancytopaenia was the indication for BME in only 
19.8% (17/86) of patients.   
 
In this paediatric study, the most common isolated cytopaenia identified in 
patients who had a BME done was isolated anaemia, defined according to 
age-related values (42). Literature has reported anaemia as the most 
common haematological abnormality in HIV-infected patients, occurring in 
10-20% of cases at the time of presentation and in 60-80% of patients 
over the course of the disease (43).   
 
Anaemia in HIV-infected individuals often has a multifactorial aetiology as 
eluded to in section 1.5.1.1 In this study, anaemia was present in near 
equal numbers among those patients diagnosed with non-specific 48% 
(n=12) and specific 52% (n=13) disease on BME. NSD was present 
mostly in the form of anaemia of chronic disorder.  
 
In patients with isolated anaemia as an indication for BME, the most 
common SD identified was opportunistic infections as a group. This 
included parvovirus infection (n=7), disseminated MAC infection (n=2) and 
disseminated MTB Complex infection (n=1). HIV-related malignancy 
namely non-Hodgkins lymphoma (n=3) formed the remainder of patients 
with specific disease on BME that had isolated anaemia as an indication 
for the procedure.  
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The literature recommends assessing iron stores and vitamin B12 and 
folate levels in the routine assessment of HIV-positive patients with 
anaemia to identify haematinic deficiencies in these patients (23).  As is 
evident from section 3.5.4 above, the majority of patients in this cohort had 
a normal MCV-value. Despite this, haematinic investigations were done in 
nearly a third of patients (29%). This has important cost implications, as 
the majority of these with normal MCV-values did not have any haematinic 
deficiency. Similarly, in those patients with low MCV-values, vitamin B12 
and folate levels were done in addition to iron studies, while low MCV-
values are not commonly associated with a vitamin B12 or folate 
deficiency state. The recommendation is that MCV-values should be used 
as a guide to direct haematinic investigations appropriately and cost-
effectively. 
 
The effect of other possible contributors to anaemia namely AIHA and 
drug-induced anaemia were not specifically analysed in this study, but 
should be borne in mind as further contributors to anaemia in HIV-infected 
children.  
 
With regards to yield per indication, no statistically significant association 
was found between any specific clinical or haematologic indication and 
finding on BME.  
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NSD however, was the major finding irrespective of whether the indication 
was clinical or haematologic. 
 
A South African study among HIV positive adults (83) evaluated the 
indications for, and yield of, a BME as used by adult physicians and found 
that a BME should be reserved for when a patient is critically ill, or in 
geographic areas where opportunistic diseases such as histoplasmosis or 
leishmaniasis are prevalent or suspected. 
 
In an earlier study by Brook et al (41), the highest yield of SD on BME in 
adult studies was found in patients with extremely advanced HIV disease, 
fever of unknown origin, pancytopaenia, and in the staging or investigation 
of lymphoma. 
 
In the study by Tanaka et al (40) from Brazil, it was found that if fever of 
unknown origin alone was the indication for BME, it was only associated 
with a finding of SD in 3.7% (3/82). If cytopaenias alone (type of 
cytopaenias not defined), was the indication for BME, it was associated 
with a finding of SD in 4.9% (4/82). The highest diagnostic value was 
found if the indication for BME was both fever and cytopaenias in 25.6% 
(21/82). In this study, 85.3% (70/82) of patients were on HAART, but 
adherence was only reported in 65.8% (54/82).  
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The Brazilian study (40) accentuates that after the introduction of HAART, 
the value of a BME in HIV-positive patients with fever and cytopaenia 
without obvious localizing signs may prove useful in identifying 
disseminated OI’s and/or malignancies. It further found that fever of 
unknown origin is mostly due to mycobacterial infections in this population.  
 
In the current paediatric cohort where the majority of patients were not 
taking HAART, neither fever nor cytopaenia was significantly associated 
with SD on BME. A disadvantage in my study was that fever was grouped 
as part of the clinical indications for a BME and not clearly defined and 
evaluated separately, thus making any conclusions about the value of 
fever as an indication and possible predictor of a positive BME difficult in 
this cohort.  
 
In my study, pancytopaenia was the least common haematologic 
indication for a BME, suggesting that, in this paediatric cohort, a BME is 
requested earlier by health care practitioners - even if only isolated 
cytopaenia or bicytopaenia is present. In the majority of these cases, NSD 
was found on BME. This compares favourably with the study by Brooke et 
al (41), showing that a low yield was found if BME was done in patients 
with isolated thrombocytopaenia, anaemia or leucopaenia, as HIV is 
usually the underlying cause in patients not yet on HAART.  
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An important recommendation following from the above mentioned studies 
is to discourage a BME if patients present with isolated cytopaenia or 
bicytopaenia, and to favour the initiation of HAART first with follow-up of 
the cytopaenias, as anti-retroviral therapy has been shown to be the 
definitive treatment of HIV-related haematologic abnormalities (13). This is 
of particular relevance in this paediatric cohort, as the majority of patients 
73.9% (51/69) were not on HAART. 
 
A further incentive for initiating HAART is that the diagnostic value of a 
BME is increased in patients with fever and cytopaenia who are already 
on HAART as shown by Tanaka et al (40). 
  
 
4.2   Utility of BME to diagnose disease 
 
In the current study, NSD, defined as HIV-related changes, anaemia of 
chronic disorder and “peripheral cause for cytopenia” without the presence 
of concomitant SD, accounted for the majority of bone marrow findings in 
55.8% (48/86).  
 
SD was identified in 37.2% (32/86) of patients.  
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An insufficient sample was reported in 7% (6/86), reflecting the technical 
difficulties often encountered in attempting to perform a BME on a young 
child.  
 
 
 NSD 
 
NSD, defined as HIV-related changes only, was the most common finding 
on BME in this paediatric cohort in 55.8% (48/86) of cases. As referred to 
in section 1.6.1.1, the common pathological features attributed to HIV 
infection found in the bone marrow of HIV positive patients include 
hypercellularity, myelodysplasia, plasmacytosis and lymphocytic and 
histiocytic infiltrates. Reticular fibrosis, evidence of reticulo-endothelial 
blockade with iron deposition, vascular congestion and mucoid 
degeneration of fat were frequently observed (74).  
  
In one of the few paediatric studies on the bone marrow features in 
children with HIV infection and peripheral blood cytopaenias by Meira et al 
(95), it was found that HIV-related changes in paediatric bone marrows 
were similar to those found in adults. 
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 SD 
 
The yield of SD on BME in my study was 37.2% (32/86), comparing 
favourably with both local and international data. The current study did not 
examine whether a specific diagnosis was made exclusively by BME, and 
thus can not comment on the value of BME in making a unique diagnosis 
of specific disease in children. This would require further study.  
 
The South African study by Karstaedt al (83) documented a similar high 
yield of 38% of SD on BME in adults. However, in their study, the BME 
gave a unique diagnosis in 24% of cases. Several studies from developed 
countries have documented a yield of 25-42% of SD on BME (79) (81) 
(82), but with diagnoses unique to the bone marrow in only 8-10% of 
cases.  
 
Blood culture facilities for mycobacterial culture were already available in 
developed countries at the time of study and this influenced the value of a 
BME in producing a unique diagnosis of specific disease in HIV+ patients. 
 
The South African study (83), with its high rate of unique diagnosis on 
BME was conducted before lysis centrifugation blood culture for 
mycobacterial disease (TB BACTEC) was available, and the authors 
concluded that their yield of unique diagnosis would have been much 
lower had mycobacterial blood culture facilities been available.  
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Numerous studies have found that the diagnostic sensitivity of a blood 
mycobacterial culture is equal to a BM  mycobacterial culture in identifying 
disseminated mycobacterial infection, and have recommended that a 
single lysis centrifugation blood culture should be the first step in the 
routine evaluation of HIV-infected adults when disseminated 
mycobacterial infection is suspected (74) (81). 
 
One could thus speculate that the same would hold true as far as 
diagnosing disseminated mycobacterial infection in HIV-infected children 
is concerned. Should this same recommendation be applied in children, it 
would be particularly advantageous as a blood culture is certainly a much 
less invasive investigation compared to a BME.   
 
Specific diseases identified in the current study were bone marrow 
granulomas (n=12), PRCA (n=11), malignancy (n=7) and a positive BM 
culture for opportunistic pathogens (n=7). No AFB’s or fungal elements 
(hyphae) were identified on microscopy in this cohort of patients.  
 
 
 Granulomas and bone marrow cultures 
 
Granulomas are the typical inflammatory response formed in response to 
a persistent antigen or as a hypersensitivity reaction. The presence of 
granulomas should alert the clinician to the high probability of an OI 
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ranging from 80 to 100% (41), especially in countries with a high 
mycobacterial, especially tuberculosis, incidence such as South Africa. As 
referred to in section 1.6.2, the etiologic spectrum of granulomata can 
encompass a variety of disorders besides mycobacterial and fungal 
infections.  
 
In the current paediatric study, granulomas on BME were identified in 14% 
(12/86) of cases. The majority of patients (70%) (7/10), with granulomas 
on BME were not on HAART yet, had advanced immunosuppression, 
namely stage four clinical disease in 83% (10/12), immunological category 
three disease in 70% (7/10), and not virally suppressed in 80% (8/10). In 
the 3 patients with granulomas identified on HAART, there remains a 
possibility that the granulomatous inflammation could have been 
attributable to the HIV-infection and not true mycobacterial infection 
especially in view of the negative ZN-stain and mycobacterial culture, and 
that the unsuppressed viral load in the other patient contributed to the 
susceptibility to mycobacterial infection.  The presence of granulomas in 
these patients on HAART does not change the conclusion that it is unlikely 
to detect granulomas in patients on HAART that are well and virally 
suppressed, and that a BME is not indicated in this population. 
 
A South African study among HIV-infected adults (83) has reported a 44% 
incidence of granuloma formation on BME. This figure is higher than the 
20-30% incidence of granuloma formation from internationally published 
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studies (76) (79). The higher incidence of granuloma formation in South 
African adults may reflect the high prevalence of mycobacterial infection in 
South Africa.  
 
In the same study however (83), it is not stated what the distribution of 
disease stage among their patient cohort was. This is important to know, 
as a relatively intact immune system is required for granuloma formation, 
and in a cohort with more advanced immune suppression, granuloma 
formation would be expected to occur less frequently. This may be the 
explanation for the 14% incidence of granuloma formation from the current 
paediatric study, where a significant proportion of the cohort had 
advanced disease.  
 
Only 5 of 12 patients (41.7%) with bone marrow granulomas had a 
positive bone marrow mycobacterial culture (MTB in 2, MAC in 3) as well.  
The remaining 58.3% (7/12), had granulomas on BME, but a negative BM 
mycobacterial culture.  
 
A common clinical practice in South Africa, with its high incidence of 
mycobacterial infection, especially tuberculosis, is to start empiric anti-
tuberculosis treatment based on the histopathological finding of a bone 
marrow granuloma, before waiting for culture confirmation. This would 
have been micriobiologically appropriate in only 5/12 patients (41.7%) with 
bone marrow granuloma and a subsequent positive mycobacterial BM 
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culture. Nevertheless, given the high incidence of mycobacterial infections 
among HIV-infected individuals in South Africa, the finding of a bone 
marrow granuloma should prompt the treating clinician to seriously 
consider empiric anti-tuberculosis treatment, and to follow-up the BM 
culture and clinical response to treatment.  
 
Very few patients in this study had positive ZN staining of the bone 
marrow. Similar findings have been reported previously with low numbers 
of positive stains identified in other studies (81) (96) (97), and 
recommendations were made for the ZN stain to be replaced by, or used 
in combination, with two other stains namely the auramine-rhodamine 
stain, and the polyclonal antibody to Mycobacterium bovis. These stains 
are not in widespread use in the public health sector in South Africa at 
present.  
 
 
 PRCA 
 
 PRCA was the second most common SD identified on BME in this cohort 
(n=11), and accounted for a third, 34.3% (11/32), of cases of SD on BME. 
Human parvovirus B19 infection has been reported as one important 
cause of acquired PRCA in HIV-infected individuals (51).  
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The diagnosis of parvovirus B19 infection is made on the pathological 
basis of characteristic giant pronormoblasts in the bone marrow, and/or a 
positive PCR for parvovirus B19 DNA on a peripheral blood or BM 
specimen. 
 
A BME though, is not essential to diagnose Parvovirus B19 as the cause 
of cytopaenias, as the diagnosis may also be made from a PCR-test for 
Parvovirus B19 DNA on a peripheral blood sample (98). 
 
In this paediatric cohort, (7/11) patients had giant pronormoblasts 
morphologically characteristic of Parvovirus B19 infection of the bone 
marrow, and (4/11) patients had PCR-proven Parvovirus B19 infection of 
the bone marrow. Correlation of bone marrow Parvovirus B19 positivity 
with PCR-testing for Parvovirus B19 in the peripheral blood was not 
undertaken in this cohort and forms an opportunity for further study. 
 
Identification of Parvovirus B19 has important therapeutic implications as 
treatment is available in the form of intravenous immunoglobulin therapy  
to ameliorate the haematologic abnormalities and decrease transfusion 
requirements. More importantly though, is that multiple reports suggested 
that the institution of HAART will result in the spontaneous clearance of 
parvovirus B19 infection, with subsequent improvement in the cytopaenias 
(99).  
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This forms an important recommendation to initiate HAART whenever 
Parvovirus B19 is identified during the evaluation of cytopaenias, and that, 
according to the above-mentioned studies reported in adults (51) (98), a 
PCR-test can identify this organism from a peripheral blood specimen, so 
that a BME is not essential when this diagnosis is considered.   
 
 
 Malignancy 
 
The third most common specific disease identified on BME was a 
malignancy. In this cohort, BM involvement by a non-Hodgkin’s lymphoma 
accounted for 21.9% (7/32) of SD identified on BME, and for 8.1% (7/86) 
of cases overall.  
 
 In all 7 cases of malignancy involving the bone marrow, the malignancy 
was a non-Hodgkins lymphoma. This corresponds to literature reporting 
that the most common malignancy in immunosuppressed children, 
whether secondary to HIV-infection or otherwise, is a non-Hodgkins 
lymphoma (100). 
 
In this paediatric cohort, fifteen patients (17.4%) had a diagnosis of non-
Hodgkins lymphoma established from another site, all of these patients 
underwent BME as a staging procedure, and 5/15 (33.3%) had confirmed 
disseminated non-Hodgkins lymphoma involving the bone marrow.  
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In 2/15 (13.3%) patients, the non-Hodgkins lymphoma was primarily 
diagnosed by BME. The indication for BME in these 2 patients was bone 
pain and ascites respectively, leading to a clinical suspicion of 
disseminated malignancy.  
 
Most cases of lymphoma in children with AIDS present with extranodal 
manifestations such as organomegaly, jaundice or abdominal distention 
with or without ascites, bone marrow involvement or central nervous 
system symptoms. It is thus important to maintain a high index of 
suspicion for possible disseminated malignancy when these clinical 
features are present and a BME would be an appropriate investigation to 
rule out disseminated malignancy involving the bone marrow. A study in 
HIV positive adults has confirmed that a high yield was found if a BME 
was done in the investigation or staging of lymphoma (41). 
 
 
4.3   Patient characteristics and bone marrow findings 
 
Clinical data was available for 69/86 patients who underwent a BME in this 
cohort of patients. The aim was to test the association between different 
variables and findings on BME.  
 
As can be seen from table 3.5, three variables were significantly 
associated with the finding of NSD on BME, namely advanced clinical 
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disease stage (p=0.05), not virally suppressed (p=0.03), and not on 
HAART at the time of BME (p=0.05). 
 
The spectrum and pathogenesis of bone marrow abnormalities in HIV-
infection has been described in section 1.0. Bone marrow abnormalities 
are frequently encountered in patients with HIV-infection with 40 – 60% of 
HIV-positive patients having dysplastic erythroid or myeloid bone marrow 
progenitor cells. The morphologic changes on BME in children were 
similar to those seen in adults (101). It is not surprising that NSD are the 
most common abnormality found on BME in HIV-positive patients (85), 
especially when not on HAART.  
 
The plasma HIV RNA titer (viral load) is a strong predictor of the speed of 
progression of HIV-infection and hence the severity of the haematologic 
manifestations of HIV-infection. This is especially true in the first six 
months of life, and it was reported that an inverse correlation exists 
between viral load and the age of patients (102). Rapid disease 
progression and higher viral loads are generally seen in children 
compared to HIV-infected adults as reported in the study by Meira et al 
(95). In this paediatric cohort, although the numbers were small, all the 
infants less than 1 year of age (4/69) had unsuppressed viral loads, and 
all had NSD on BME.  
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It is thus possible that especially in younger patients, not on HAART and 
with a high viral load, the incidence of HIV-related changes on BME could 
be even higher – providing further strength to the recommendation to start 
HAART early to ameliorate the bone marrow changes and resultant 
haematologic abnormalities in these patients. Earlier initiation of HAART in 
infants less than 1 year of age forms part of the recently updated new 
treatment guidelines for children with HIV from the Department of Health 
stating that all children less than 1 year of age should be initiated on 
antiretroviral therapy regardless of CD4 count (12). 
 
In this paediatric cohort, no single variable was significantly associated 
with the finding of SD on BME.  
 
Literature from adult studies reports a varying spectrum of findings when a 
BME is done on HIV-infected patients. These findings ranged from      
HIV-related changes only (103), to identifying variables which may be 
associated with SD. A history of prolonged fever and an elevated direct 
bilirubin, was found to be associated with disseminated OI by logistic 
regression analysis in one study (82). 
 
A recent study (85) from a major adult HIV/AIDS treatment centre in 
London, UK, found normal or HIV-related changes in the majority of 
BME’s. In those that had SD on BME, the diagnostic yield was highest if 
cytopaenia and fever co-existed in the absence of localizing signs of 
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infection. If fever without cytopaenias and cytopaenias without fever were 
present, a BME had significantly less diagnostic value. All the patients in 
this study were on HAART already.   
 
A common problem with most reported studies on all the aspects 
pertaining to BME’s in HIV-positive patients, is that their patient population 
differ significantly from the current paediatric cohort studied. These studies 
are often from specialist clinics in developed countries, inner-city adult HIV 
clinics, HIV-infection acquired through homosexual transmission and 
intravenous drug abuse as opposed to mainly vertical transmission in 
children. In light of this, one should be cautious in applying the results 
from these studies to paediatric patients from sub-Saharan Africa as the 
context is vastly different.  
 
Many reported studies are retrospective series with small patient numbers, 
in different settings (some outpatient and others inpatient-based), different 
exposure of patients to antiretroviral therapy, different or undisclosed 
disease stage of patients, and an uncertainty as to whether confounding 
variables that may influence variables were controlled for in all cases. 
Whether the BME provides a unique diagnosis or merely the same 
diagnosis from a different site, is also not always stated. This makes 
comparison between studies and recommendations based on data 
extrapolated from adult studies difficult.  
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5.0 CONCLUSION  
 
In this paediatric cohort, the patient population can be defined as HIV 
positive children with advanced disease stage, the majority not on 
HAART, and mainly from an inpatient-setting in a tertiary hospital.  
 
This retrospective, cross-sectional descriptive study aimed to identify the 
indications for BME in HIV+ children, the yield per indication for BME, the 
utility of BME to diagnose SD, and to describe the association (if any) 
between different patient variables and the finding of SD or NSD on BME. 
 
The major findings were that BME’s were requested by health care 
practitioners for a wide variety of clinical and haematologic indications, but 
that no statistically significant association was found between specific 
indications and finding on BME.  
 
Isolated cytopaenia and bicytopaenia were the most frequent 
haematologic indications for this invasive procedure, despite it’s low yield 
of SD in previously reported studies (40) (41).  
 
As expected, given the advanced disease stage of these patients, non-
specific HIV-related changes were found in the majority 55.8% (48/86).  
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The BME identified SD in 37.2% (32/86) patients, but the study did not 
examine whether this finding of SD on BME was unique to the bone 
marrow.  
 
The most common SD identified were OI’s as a group.  
 
The following patient variables were significantly associated with the 
finding of NSD (HIV-related changes) on BME, namely advanced clinical 
disease stage (p=0.05), unsuppressed viral load (p=0.03), and pre -
HAART (p=0.05).  
 
Problems incumbent in any retrospective study were encountered namely 
the incompleteness of data and clinical, laboratory and therapeutic data 
was only available for 69/86 patients who underwent a BME during the 
study period. The study numbers are small and findings should be 
confirmed by larger, prospectively designed studies controlling for other 
variables which may influence the outcome and select patients that are 
representative of the paediatric HIV-positive community at large. 
 
The majority of patients were referred from the general paediatric wards 
as inpatients, and as no standard referral protocol exists with regard to 
HIV-infected children with haematologic abnormalities, referral bias may 
have contributed to some patients being referred for a BME and others 
not, despite identical clinical presentations. 
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Most patients in this study were inpatients, symptomatic and newly 
diagnosed. They had advanced disease stage, unsuppressed viral loads 
and low CD4 counts. Thus, the sample is not representative of the general 
paediatric HIV-population at large and further study from a variety of 
settings in which patients across the stage-spectrum of HIV-infection is 
seen is necessary before general inferences about HIV-infection and bone 
marrow abnormalities can be made.  
 
Despite the small numbers, retrospective nature and patient population 
that is slanted towards patients with advanced disease, the value that this 
study adds is that careful consideration should be given to instituting 
HAART first in the setting of non-critically ill patients with advanced 
immunosuppression, not on HAART, and with an unsuppressed viral load, 
before embarking on an invasive procedure such as a BME to explain 
haematologic abnormalities or search for OI’s.  
 
Less invasive procedures such as peripheral blood testing for 
mycobacterial infections (BACTEC) and Parvovirus B19 PCR-testing have 
been shown to be of equivalent value to bone marrow in diagnosing 
disseminated OI’s (74) (81) (98), and these would be more appropriate 
initial investigations. 
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 Prospects for future studies would be to evaluate the value of a BME in 
patients that are on HAART and present with fever without localizing signs 
and cytopaenias as this has been shown to produce the highest yield of 
SD in the HAART-era (40).  
 
This paediatric cohort study highlights the fact that, as in adults, a BME is 
not an undisputed panacea for providing the answer in HIV-positive 
patients in whom disseminated OI’s or malignancies are suspected, and 
sound clinical judgement and appropriate ancillary investigations should 
prevail before referring children for this invasive procedure. 
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               Appendix A 
 
 
DATA COLLECTION SHEET 1
No.
                Indications for BME        Confounders                                       Histopathology Culture BME+ for
Clinical Hematological      H/D       B/I Drugs              Specific disease Non-specific disease        Other Pos Org Neg any spec dis.
LOW Pers fever HSM LAP Susp OI / M Staging Other Isol cyto Bicyto Pancyto Other Y N ND Y N ND Y N AFB'S Granuloma Fungal Malignancy Parvo HIV  ONLY ACD Norm PC Other Insuff
KEY
BME Bone marrow examination AFB Acid fast bacilli
Y Yes
N No 
ND Not done
LOW Loss of weight Parvo Parvovirus B19 infection
Pers fever Persistent fever ACD Anaemia of chronic disorder
HSM Hepatosplenomegaly PC Peripheral cause for cytopaenia
LAP Lymphadenopathy Dx Diagnosis
Susp OI/M Suspected opportunistic infection or malignancy Insuff Insufficient for analysis
Isol cyto Isolated cytopaenia HIV related HIV Related changes on BME
Bicyto Bicytopaenia
Pancyto Pancytopaenia
H/D Haematinic Deficiency
B/I Documented Bacterial Infection
Drugs Y Yes if on Bactrim, Ganciclovir, Dapsone or antineoplastic chemotherapy
N No
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                Appendix B 
 
DATA COLLECTION SHEET 2
NO. BME Findings SEX                 AGE    HAART Other Rx                                        STAGE    Nutr. Def        Blood Abnormalities       B/C Known opp Known  HIV
1 2 M F < 1 YR 1-5 YRS >5 YRS PRE ON U Y N U  Clinical          Immunological   Viral Load Fe B12 / Fol ND Nil Isol. Cytop Bicytop Pancytop No abn Pos Neg ND infx on Rx malignancy
Specific Non-specific 1 2 3 4 U Cat I Cat II Cat III VL < 25 VL > 25 Y N Y N
disease disease CD4 >25 % CD4 15-24%CD4 <15%
KEY
BME Findings Bone marrow examination findings
1 Specific disease: Disseminated opportunistic infections or HIV-related malignancy
2 Non-specific disease: HIV-related changes, anaemia of chronic disorder or peripheral cause for cytopaenia
M Male
F Female
HAART Highly active antiretroviral treatment
Pre Not on HAART, or on HAART for less than 3 months at time of study or an interrupted period of HAART in preceding 3 months
On On HAART for more than 3 months
Other Rx Other treatment: Y if on Bactrim, Ganciclovir, dapsone, amphotericin B or anti-neoplastic chemotherapy
U Unknown
Nutr def Nutritional deficiency
Fe Iron
B12/Fol Vitamin B12 / Folate
BC Blood culture
Pos Positive Neg Negative ND Not done
Opp Infx Opportunistic infection
HIV-related malignancy Non Hodgkins lymphma
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